Business
Results of the 2026 Annual General Meeting for the 2024/25 Financial Year of BRAIN Biotech AG
ZWINGENBERG, GERMANY - March 11, 2026 (NEWMEDIAWIRE) - At today's Annual General Meeting of BRAIN Biotech AG (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN 5203949), shareholders approved all agenda items with a broad majority. Dr. Ursu...
About this update from Brain Biotech Ag
[{"type":"table","headerItems":[],"items":[{"val":[{"val":[{"type":"text","content":"ZWINGENBERG, GERMANY - March 11, 2026 (NEWMEDIAWIRE) - At today's Annual General Meeting of BRAIN Biotech AG (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN 5203949), shareholders approved all agenda items with a broad majority.","length":242,"tagName":"p"},{"type":"text","content":"Dr. Ursula La Cognata of Berlin, the managing partner of ybe (Your Biotech Experts Partnership), was elected to the Supervisory Board by the Annual General Meeting for a term of four years. She had already been appointed by the Darmstadt Local Court as a new member of the Supervisory Board, effective 11 July 2025, until the next Annual General Meeting.","length":354,"tagName":"p"},{"type":"text","content":"In his statement to shareholders, Supervisory Board Chairman Dr. Michael Majerus said: "We remain convinced that BRAIN Biotech AG has many positive development opportunities thanks to its successful product business, its strong market position in contract research, the expected revenues from the monetization initiatives as well as licensing of pharmaceutical projects, and further product innovations from the BRAINBioIncubator."","length":441,"tagName":"p"},{"type":"text","content":"Agile organizational structure enables fast and flexible customer solutions","length":75,"tagName":"p"},{"type":"text","content":"In his speech, CEO Adriaan Moelker commented on the company's strategy, stating: "We remain convinced that our two-pillar strategy, with the product-oriented BRAINBiocatalysts segment on the one hand and the BRAINBioIncubator segment on the other, is the right strategy. This approach enables us to continue to monetize our investments, achieve scientifically based breakthroughs, and organically expand a profitable, scalable, enzyme-focused business. Here we can offer our customers truly unique selling points.","length":522,"tagName":"p"},{"type":"text","content":"According to Moelker, one of the group's unique selling points is that, due to its relatively small size, it can respond quickly and flexibly to customer needs with short communication channels and offer innovative biotechnological solutions. The CEO emphasized the importance of maintaining this advantage, even when the company experiences stronger growth in the future.","length":376,"tagName...